ATR inhibition augments the efficacy of lurbinectedin in small cell lung cancer
C. W. Schultz, Y. Zhang, R. Elmeskini, A. Zimmermann, H. Fu, Y. Murai, D. Wangsa, S. Kumar, N. Takahashi, D. Atkinson, L. K. Saha, C.-F. Lee, B. Elenbaas, P. Desai, R. Sebastian, , A. Thomas
This study shows that combining ATR inhibition with lurbinectedin improves efficacy in SCLC, particularly in MYC-driven non-neuroendocrine tumors.
EMBO Molecular Medicine · Aug 7, 2023Peer-reviewedCancer Biology